Genomics in Cancer Care Market Size & Share | Growth Analysis 2035

Genomics in Cancer Care Market Size and Forecast

According to analysts at Vantage Market Research, the Global Genomics in Cancer Care Market reached USD 24.5 billion in 2024 and is projected to reach USD 131.7 billion by 2035, at a compound annual growth rate (CAGR) of 16.55% between 2025 and 2035. The market is expected to grow in the coming years due to increasing demand for diagnostics, as well as the introduction of technologically advanced and cost-effective diagnostic technologies. Growing investment in the biotech and pharmaceutical sectors, along with increasing R&D operations for the development of new and breakthrough treatment methods, essentially drives the growing share of the genomic segment in the cancer care market. Additionally, the increasing demand for personalized medication during the forecast period is expected to drive demand further.

Download Sample Report PDF (Including Full TOC, Table & Figures) @ https://www.vantagemarketresearch.com/genomics-in-cancer-care-market-1285/request-sample

The key growth factor was the growing prevalence of cancer cases and the rising demand for personalized treatment. In 2022, the WHO (World Health Organization) recorded 20 million new cases of cancer and 9.7 million deaths. Further supporting the market growth are technological innovations, rising investments, growing research and development activities, and a decline in sequencing costs.

Cancer is the second leading cause of death worldwide, responsible for nearly 10 million deaths in 2020 alone. Increasing cases of cancer are paving the way for novel and advanced treatment options and many government initiatives on cancer and genomics. One such initiative was the launching of GenomeIndia, a research project by the government of India in January 2020, sponsored by the Department of Biotechnology, Ministry of Science and Technology. GenomeIndia’s genetic sequencing of this population can enhance the applicability of genetics in personalized medicine, empowering researchers and clinicians to identify genetic diagnoses of rare and complex disorders and ultimately leading to advancements in the genomics market.

Technological innovations, such as high-throughput sequencing (NGS), introduced in the life sciences, are also propelling market growth. A research study published by the National Library of Medicine in October 2021 claims that the improvement in sequencing efficiency brings the cost down to less than USD 100 per person.

Next-generation sequencing (NGS) using Illumina is a sequencing technology that determines the order of nucleotides in the entire targeted region of RNA or DNA, which can be utilized for various applications in laboratories. The technology is highly effective, more affordable, and less time-consuming.   Such technologies are also expected to contribute to market growth.

Emerging as veritable pathbreakers in genomics are new DNA sequencing techniques. Companies are stepping up to advance this technology and enable the expansion of genomics in cancer treatment. For example, the National Human Genome Research Institute (NHGRI) supports the research and development of new technologies and methods in DNA sequencing through its Genome Technology Program.

Cancer is a genomic disease, an acquired disease of the genome,  and most cancers are caused by acquired genomic variants. Progress in the field is transforming oncology practice and quickly benefiting patients. The growing prevalence of cancer cases and the demand for cancer treatment are also expected to drive investment in genomics. Genomic technology, research, and development firms are emerging. For example,  Illumina Accelerator, a business accelerator partner of Illumina Inc., took stakes in seven genomics startups in September 2021.

Industry Growth Factors

Having a better understanding of the cancer genomics perspective enables us to develop personalized medicine approaches that are tailored to individual needs.  By understanding a patient’s unique genetic makeup, treatment plans can be customized based on the individual’s genetic profile as well as the type of cancer. Such targeted therapies enhance treatment efficacy and reduce adverse effects, resulting in an increased demand for genomic-based therapies.

Moreover, the growing emphasis on genomic research also propels market growth by promoting the creation of new genomic technologies and therapies. So, the increasing incidence and prevalence of cancer is driving the market growth.

Industry Restraining Factors

The high cost of genomic testing can exacerbate disparities in healthcare access, particularly in low- and middle-income regions or underserved populations. These disparities may lead to unequal access to advanced genomic technologies and personalized treatments, which may have an adverse impact on overall market growth and result in the negation of equitable cancer care. Thus, the high costs involved in genomic testing limit market growth.

The market leader is competing with other players in the market for innovative products and services. The above representation shows the revenue share percentage for some of the top players in the overall market. Market players are devising various strategies to cater to the demand emerging from different industries. The major growth strategies in the market are Acquisitions.

Exclusive 30% Instant Discount on Direct Purchases @ https://www.vantagemarketresearch.com/buy-now/genomics-in-cancer-care-market-1285/0

Competition Landscape

There is a high level of competition in genomics within the Cancer Care Market due to rapid technological advancements and the growing demand for personalized medicine. These include innovative genomics assay technologies, diverse data analytics capabilities, and a powerful bioinformatics platform. Companies necessarily focus on providing better accuracy — in cancer diagnostics,  treatment selection, and monitoring, among other areas. Regulatory compliance and data privacy are also key issues, with market leaders focusing on integrating multi-omic data to improve the time to therapeutic outcome.

Some of the Major Players operating in the Global Genomics Market of Cancer Care are- Illumina Inc., Agilent Technologies, Inc, Roche Diagnostics, GE Healthcare, Abbott Laboratories, Bio-Rad Laboratories, Inc. Major companies have been involved in adopting various strategic initiatives such as developing new products, collaborations with institutions and other industries, partnerships.

• Illumina Inc.: A company with a significant presence in the genomics and human health sectors, contributing to the advancement of precision medicine. The company offers sequencing and array solutions, featuring a comprehensive portfolio that encompasses both integrated sequencing and microarray systems. The company is also undertaking strategic initiatives to expand its genomics portfolio, providing solutions within this space.
• F. Hoffmann-La Roche Ltd. produces diagnostics to help inform their targeted treatments and has developed personalized therapeutics tailored to individual genetic and disease profiles. The company has a diverse sequencing product portfolio, including sample preparation reagents, NGS oncology assays, the MagNA Pure 96 system for NGS automation, the KAPA HyperCap workflow, and the KAPA HyperExome V2 Probes.

Top Key Companies:

• Agilent Technologies
• Illumina Inc.
• Pacific Biosciences Inc.
• ThermoFisher Scientific Inc.
• Intrexon Bioinformatics Germany GmbH is a major company operating in the Global Genomics in Cancer Care Market.

Recent Developments

• Beckman Coulter Life Sciences launched the Illumina TruSight Oncology 500 DNA/RNA assay for automatizing oncology research on the Biomek NGeniuS System in August 2024. Myers also accelerated genomic profiling of tumor samples by utilizing this tool, which can analyze up to 24 libraries per batch at a fraction of the traditional costs and in significantly less time.
• April 2024: Allegheny Health Network and Bio-Rad Laboratories collaborated to investigate the application of Bio-Rad’s Droplet Digital PCR (ddPCR) technology for monitoring molecular residual disease (MRD) in solid tumors. The partnership would contribute to more precise and sensitive monitoring of MRD, with the potential to improve patient outcomes for diseases and conditions that can benefit from timely intervention and treatment, including cancer.
• April 2024: Bio-Rad Laboratories launched the ddPLEXESR1 Mutation Detection Kit, a multiplexed digital PCR assay for the co-detection of seven ESR1 mutations with a sensitivity of 0.01%. Coupled with the QX600 System, it delivers fast, simultaneous readouts of ctDNA or FFPE samples, further advancing oncology research and patient surveillance.
• F. Hoffmann-La Roche Ltd. Collaborates with AWS to Bring AI-Powered Tools to Navify Digital Pathology Platform (Oct 2023): F. Hoffmann-La Roche Ltd. has partnered with cloud computing company AWS to integrate AI-powered tools into its Navify Digital Pathology platform. Leveraging cloud infrastructure for quantity, flexibility, and protection, this partnership improved the diagnosis of breast and prostate cancer by making pathology labs faster, more accurate, and more efficient.
• In November 2021, GE Healthcare announced its partnership with SOPHiA GENETICS to expand access to advanced care, enhance the availability of precision medicine, and support cancer patients.
• September 2021: Partnered with Applied Microarrays Inc. to bring another facet into its diagnostics business, with the scope of the deal expanding its manufacturing footprint in the United States.

For in-depth competitive analysis, buy now and get up to 25-35% Discount At: https://www.vantagemarketresearch.com/buy-now/genomics-in-cancer-care-market-1285/0

Segmented Insights

Application Insights

Based on application, the market is segmented into diagnostics, personalized medicine, drug discovery & development, and research. In 2023, the diagnostics segment accounted for 39% of the revenue share in the genomics market for cancer care. Genomic diagnostics play a key role in the early detection and precise identification of cancer.

The diagnostics segment held the largest market share in revenue in 2023. The increasing incidence of rare inherited diseases, as well as their diagnosis and treatment, are major driving factors behind this growth. This is a timely approach, as whole-genome sequencing could help diagnose the genetic disease quickly, and researchers are already working on it. According to Illumina Inc., 49-75% of children whose whole genome was sequenced experienced a positive outcome. For example, a pediatric patient diagnosed with a genetic mutation after 7 years of testing without benefit, with WGS, was diagnosed with eta-propeller protein-associated neurodegeneration (BPAN).

The drug discovery and drug development segment is expected to record the fastest CAGR during the forecast period. The rise of rare diseases, where 85% of them are ultra-rare, aiming for one in a million for drug discovery and development, is a major issue for healthcare specialists. For example, in July 2021, Deep Genomics raised USD 180 million in investment to scale its AI discovery platform and develop its portfolio.

By Application

• Diagnostics
• Personalized Medicine
• Drug Discovery & Development
• Research

Product Insights

On the basis of products, the market can be segmented into instruments, consumables, and services. In 2023, the services segment accounted for a 21% revenue share in the genomics market for cancer care. As genomic technologies continue to evolve, the scope of genomic data analysis and interpretation becomes increasingly complex.

Instruments held the largest regional market share at 54.8% in 2023. A range of genomics instruments is available to meet the needs of genomic research. For example, in March 2023, Illumina Inc. introduced the first product built on the foundation of its new technology, Illumina Complete Long Read Prep Human, for both long and short—read sequencing instruments. Its novel long-read technology is used to perform whole-genome sequencing (WGS) of humans.

As sequencing costs decreased, whole-genome sequencing (WGS) became a more accessible and affordable tool for genomic research, enabling the analysis of approximately 3 billion DNA base pairs. This provides clinicians and researchers with a long-view perspective over the whole genome, which is beneficial for discovery applications — for example, locating causative variants. Advanced technologies and cutting-edge genome sequencers are also effective in conducting whole-genome sequencing.

Based on services, the segment is projected to grow at the fastest compound annual growth rate (CAGR) during the forecast period. The growth of this segment can also be attributed to the availability of a range of genomic services provided by key market players, including genotyping services, whole-genome sequencing services,  genomic instrument services and training, sequencing services, and microarray services. For example, Illumina Inc., which provides tools for life sciences research, stated that its 2023 revenue is expected to increase due to a rise in its maintenance service contracts.

By Product

• Instruments
• Consumables
• Services

Technology Insights

The market is revenue-based on technologies such as genome sequencing, PCR, microarrays, nucleic acid extraction, and purification, among others. The PCR segment accounted for a 32% revenue share in the genomics market for cancer care in 2023. PCR has also gained wide acceptance since it is a sensitive and specific method essential for accurately detecting cancer-associated genetic material.

PCR had the highest revenue share in the market in 2023. Polymerase Chain Reaction (PCR) - A lab method for amplifying millions to billions of copies of a specific DNA segment or the DNA to be analyzed in greater detail. It is primarily driven by the rapidly growing prevalence of cancer and efforts to engineer more sophisticated and efficient diagnosing and treatment solutions. For example, in March 2022,  scientists at Queen Mary University of London developed the first PCR test to detect oral cancer, aiming to enhance the early detection and treatment of oral cancer.

Microarrays are projected to register the highest CAGR during the forecast period. Because microarrays can be used to examine thousands of genes simultaneously, they are a vital tool in the laboratory. It can aid in making a diagnosis and clarifying the complexity of the tumor. Moreover,  its capability of recognizing thousands of genes is beneficial for laboratories at an efficient price. The growth of the market can be attributed to the increase in genomics activities, the adoption of DNA microarrays, and technological advancements, such as the innovative technology of vaccine microarray patches, which have the potential to skyrocket global immunization coverage, according to UNICEF.

By Technology

• Genome Sequencing
• PCR
• Microarrays
• Nucleic Acid Extraction & Purification
• Other

Browse the Complete Summary and Table of Contents @ https://www.vantagemarketresearch.com/industry-report/genomics-in-cancer-care-market-1285

By Regional Analysis

The North America, Europe,  Asia Pacific, and LAMEA market is analyzed across each region. The genomics in cancer care market in Asia Pacific is expected to expand at the fastest CAGR during the forecast period. In the Asia-Pacific region, the incidence of cancer is increasing due to population growth, demographic aging, and changing lifestyle and environmental exposures.

North American genomics in the cancer care market accounted for a revenue share of 36.7% in 2023, thereby dominating the overall market. The increase in market growth is attributed to favorable government initiatives that promote research in the relevant field. Many companies are emerging in the genomics field and working with institutions. For example, the Mount Sinai Health System and the Icahn School of Medicine launched a new human genome sequencing program in August 2022, known as the Mount Sinai Million Health Discoveries Program, in collaboration with the Regeneron Genetics Center (RGC), a partnership with industry-based roots.

Asia Pacific: Over the forecast period, the Asia Pacific region is anticipated to register the fastest CAGR. According to the World Economic Forum's report from October 2023, Asia accounted for 45% of the world's breast cancer cases and 58% of cervical cancer deaths, making them among the common cancers in the region. This is likely to increase the gains of the genomics market in cancer care in the region as it can assist in the treatment. Genomic changes in cervical cancer, for example, suggest that existing drugs can treat the disease, according to the National Cancer Institute.

U.S.: In 2023, the U.S. genomics market in cancer care accounted for a 26.3% share of the global genomics market in cancer care. U.S. government efforts continue to help propel the adoption of genome science disciplines nationwide. The research initiatives are at a working stage to drive precision medicine based on genome sequencing. For example, in April 2023, the National Institutes of Health (NIH) reported that the All of Us program, in collaboration with 23andMe, had provided approximately 250,000 whole-genome sequences to spark breakthroughs in precision medicine.

UK: The UK genomics market in cancer care is experiencing substantial growth, driven by a surge in activities such as government initiatives and collaborations between companies aimed at expanding the market. For example, in November 2023, Genomics England and Oxford Nanopore Technologies announced a collaboration to sequence rare diseases. Such partnerships are thriving in the region, driving market growth.

Europe: In this industry, Europe’s genomics market is recognized as a profitable region for making rapid strides in genomic development. Some have formed partnerships, such as Europe’s 1 million genome effort, to prevent illness and create breakthroughs in personalized treatment. It also aimed to establish a European network of genomic reference cohorts comprising nearly half a million citizens. These initiatives are expected to drive market growth.

France’s market is expanding in genomics, led by companies forming strategic alliances in pursuit of progress in precision medicine. An example of this is the partnership between Genomic Sweden Medicine (GMS) and France Genomic Medic in October 2021. The aim of this partnership is to implement a genomics and precision medicine-based strategy in healthcare, offering better alternatives for cancer and rare diseases.

Japan: Rising cases of cancer are stepping Japan's genomics ahead in the cancer care market. The number of cancer deaths reached 380,400 in 2022, according to the National Cancer Center in Japan. To find solutions and reduce cancer deaths, Japan initiated Cancer Genomic Medicine (CGM) in June 2019, which means that cancer gene panel tests are now covered under the national health insurance system. Additionally, the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) submitted clinical and genomic data to Cancer Genomic Medicine (CGM) hospitals, academic organizations, and businesses.

China: The steady growth of the genomics cancer care market is also due to multiple partnerships and collaborations from various companies operating in the genomics domain in China. For example, in 2020, Illumina Inc. announced an extension of its collaboration with Burning Rock DX, a Chinese company specializing in next-generation sequencing for oncology diagnostics.

Research Methodology

Large sample size data collection modules are used for data collection and base year analysis. There are many ways and strategies through which the data or market-related information can be acquired; it is the stage of collecting that data. This must include reviewing and planning all the data harvested from the past in advance. It also involves examining data inconsistencies observed across multiple data sources. Market statistical and coherent models extract and conclude the market data. Additionally, the market report emphasizes key success factors, including market share analysis and trend analysis. Read more about this report here and request an analyst call or submit your inquiry.

The Vantage Market Research team employs the following key research methodologies: data triangulation (Data mining, analysis of the impact of data variables on the market, and primary validation with industry experts). Includes Data models such as the Vendor Positioning Grid, Market Timeline Analysis,  Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional, and Vendor Share Analysis. If you have any questions about the research methodology, please don't hesitate to ask, and our experts will be happy to assist you. @ Speak To Analyst

Customization Available

Vantage Market Research is a leading market research consulting firm with advanced formative research and anti-formation capabilities. Our pride is in serving our current and prospective clients with timely data and analysis that befits their purpose. Price trend analysis of target brands, understanding the market for other countries, can be incorporated on demand (upon request from the specified country list). This may include clinical trial results data, literature reviews, refurbished market analysis, and product base analysis. Target Competitors Market:  Market Analysis The market can be analyzed using technology-based analysis to market portfolio strategies. However, the beautiful thing is that we can extend the data to as many competitors as you need in the style and data format you desire. We can also provide you with the data in its crude, raw form, as Excel files or pivot tables (Factbook), or help you create presentations based on the data sets available from this research. Request for Customization

FAQ

1. What is genomics in cancer care?
2. How is genomics used in cancer diagnosis?
3. What are the latest advancements in cancer genomics?
4. How does genomic sequencing help in personalized cancer treatment?
5. What role do biomarkers play in cancer genomics?
6. How can genomics identify cancer risk factors?
7. What is a liquid biopsy in cancer genomics?
8. How does genomic profiling improve cancer treatment outcomes?
9. What is the significance of next-generation sequencing (NGS) in cancer genomics?
10. How do genetic mutations affect cancer progression?
11. What are the challenges in integrating genomics into cancer care?
12. How does genomics help in identifying targeted therapies for cancer?
13. What is the cost of genomic testing in cancer care?
14. How accurate are genomic tests in predicting cancer outcomes?
15. How does genomics guide clinical decision-making in oncology?
16. What are the ethical concerns associated with genomic testing in cancer care?
17. How does genomics impact immunotherapy in cancer treatment?
18. What are the regulatory challenges for genomics in cancer care?
19. How do genomic databases improve cancer research and treatment?
20. What is the future of genomics in cancer prevention and early detection?